Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: A prospective study

Ho, Wai–Kuen; Wei, William I.; Kwong, Dora Lai-Wan; Sham, Jonathan S. T.; Tai, Patricia; Yuen, Andrea; Au, Darren

doi:10.1002/(sici)1097-0347(199909)21:6<547::aid-hed8>3.0.co;2-y

Cited by 125 publications

(54 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although contemporary multimodality therapy is typically effective, sensorineural hearing loss (SNHL) is a common adverse effect. Cranial RT is less ototoxic than platinum-based chemotherapy (i.e., cisplatin), but is still associated with high risk for SNHL, [1][2][3] and even more so when combined with cisplatin. 4,5 Risk and severity of SNHL increases when a higher radiation dose is delivered to the temporal bone, where otologic structures reside.…”

Section: Introductionmentioning

confidence: 99%

“…4,5 Risk and severity of SNHL increases when a higher radiation dose is delivered to the temporal bone, where otologic structures reside. [1][2][3]6 Damage to any part of the auditory mechanism can cause hearing loss, 7 and the reported incidence of RT-induced SNHL varies (from 0% to 54%) across studies. 8 RT-induced histopathologic changes to the inner ear cause SNHL.…”

Section: Introductionmentioning

confidence: 99%

“…In animal models and humans, RT-induced damage to the cochlear hair cells and supporting cells, 9,10 vascular degeneration, 11 and deterioration of the basilar membrane, spiral ligament, stria vascularis, 10 spiral ganglion, and cochlear nerve 9,10 have been reported. RT-induced SNHL typically manifests several years after RT, 1,3,4,12 preferentially affects higher frequencies, 3,12,13 and can be progressive. 4 Damage to the auditory nerve and central pathways has also been reported.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer

Bass

Hua

Huang

et al. 2016

JCO

102

105

View full text Add to dashboard Cite

Purpose Patients treated with cranial radiation therapy (RT) are at risk for sensorineural hearing loss (SNHL). Although SNHL is often characterized as a delayed consequence of anticancer therapy, longitudinal reports of SNHL in childhood cancer survivors treated with contemporary RT are limited. We report the incidence, onset, severity, and long-term trajectory of SNHL among children receiving RT. Potential risk factors for SNHL were also identified. Patients and Methods Serial audiologic testing was conducted on 235 pediatric patients who were treated with conformal or intensity-modulated RT as part of an institutional phase II trial for localized primary brain tumors, including craniopharyngioma, ependymoma, and juvenile pilocytic astrocytoma. All but one patient had measurable cochlear radiation dose (CRD) greater than 0 Gy. The median follow-up from RT initiation to latest audiogram was 9 years with a median of 11 post-RT audiograms per patient. Audiograms were classified by the Chang Ototoxicity Grading Scale. Progression was defined by an increase in Chang grade from SNHL onset to the most recent evaluation. Results At last evaluation, SNHL was prevalent in 14% of patients: 2.1% had mild and 11.9% had significant SNHL requiring hearing aids. Median time from RT to SNHL onset was 3.6 years (range, 0.4 to 13.2 years). Among 29 patients with follow-up evaluations after SNHL onset, 65.5% experienced continued decline in hearing sensitivity in either ear and 34.5% had no change. Younger age at RT initiation (hazard ratio [HR], 2.32; 95% CI, 1.21 to 4.46), higher CRD (HR, 1.07; 95% CI, 1.03 to 1.11), and cerebrospinal fluid shunting (HR, 2.02; 95% CI, 1.07 to 3.78) were associated with SNHL. Conclusion SNHL is a late effect of RT that likely worsens over time. Long-term audiologic follow-up for a minimum of 10 years post-RT is recommended.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer

Bass

Hua

Huang

et al. 2016

JCO

102

105

View full text Add to dashboard Cite

show abstract

“…They maintained that the cisplatin dose was too low to induce SNHL by itself. Ho et al [17] reported that the mean dose of 275 mg/m 2 was not associated with increased hearing threshold. In the present study, total cumulative dose of cisplatin received ranged from 210 to 372 mg.…”

Section: Discussionmentioning

confidence: 99%

Effects of Chemoradiation on Hearing in Patients with Head and Neck Malignancies: Experience at a Tertiary Referral Care Hospital

Jain¹,

Banerjee²,

Dandinarasaiah

2016

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Hearing loss as a side effect in patients with head and neck malignancies with chemoradiation is frequently ignored. Its effects on auditory functions are less studied and there are studies done on animals which are less reliable. The present study was undertaken to identify the type of hearing loss and also to quantify the degree of hearing loss in these patients. A prospective, descriptive study was undertaken in histologically proven head and neck cancer patients treated with cobalt 60 teletherapy who received a dose of 60-66 Grays (Gy) over a period of 6-7 weeks with concurrent Cisplatin 30 mg/m 2 once weekly for 6 weeks. The study included 40 patients (80 ears) undergoing chemoradiation. A baseline pure tone audiometry and impedance audiometry was performed in all the cases prior to the therapy and the same was repeated immediately after the completion of treatment, at 8 and 16 weeks. The changes in pure tone level thresholds and impedance from baseline were correlated with the dose of radiation and chemotherapy. Sensori neural hearing loss (SNHL) and conductive hearing loss was observed in 82.5 and 17.5 % respectively. At the end of 16 weeks, SNHL was found in 27.5, 72.5 and 82.5 % at 2, 4 and 8 kHz respectively. In addition, Eustachian tube dysfunction and Otitis media with effusion was observed in 10 and 7.5 % of patients respectively which lead to conductive hearing loss. Further, it was noted that SNHL in patients with high risk site malignancy (81.8 %) was alarmingly higher compared with low risk site malignancy (18.1 %). The hearing loss at 62, 64 and 66 Gy in comparison to 60 Gy was statistically significant. Hearing loss, specially SNHL was the predominant finding in our study with [80 % of patients showing the inner ear damage due to irradiation of head and neck malignancies. Although, all the frequencies like 2, 4 and 8 kHz were significantly affected, SNHL was more marked in the latter two frequencies. Nearly, 90 % of the patients who had SNHL belonged to high risk site category of head and neck malignancies. Increasing the radiation dosage was directly proportional to the degree of hearing loss with the dose more than 60 Gy causing significant injury to the middle and inner ear.

show abstract

“…The www.intechopen.com reported post-radiation therapy hearing loss rates based on audiometric evaluation varied between 0% and 54% (Ho et al, 1999;Kwong et al, 1996;Raajmakers et al, 2002). This is attributed to radiation-induced damage to the sensorineural auditory pathways.…”

Section: Post-irradiation Sensorineural Hearing Lossmentioning

confidence: 99%

Ear-Related Issues in Patients with Nasopharyngeal Carcinoma

Low¹,

Rangabashyam²

2012

Carcinogenesis, Diagnosis, and Molecular Targeted Treatment for Nasopharyngeal Carcinoma

View full text Add to dashboard Cite

Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: A prospective study

Cited by 125 publications

References 12 publications

Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer

Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer

Effects of Chemoradiation on Hearing in Patients with Head and Neck Malignancies: Experience at a Tertiary Referral Care Hospital

Ear-Related Issues in Patients with Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About